TrialBioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy2021

Efficacy, Safety, and Immunogenicity of HLX02 Compared with Reference Trastuzumab in Patients with Recurrent or Metastatic HER2-Positive Breast Cancer: A Randomized Phase III Equivalence Trial.

Binghe Xu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.